A new report argues that menopause remains underserved by evidence-based therapeutics despite growing consumer attention and a rapidly expanding menopause market. The piece highlights structural barriers in women’s health research, including underfunding and underrepresentation in clinical trials, and it criticizes widespread commercialization of products with limited clinical support. The article points to scrutiny of hormone panel testing practices, citing a BMJ discussion around costly hormone panels that may not provide actionable guidance because there is no defined testing window for hormone therapy decisions. It frames the evidence gap as persistent even as telehealth and startups proliferate around symptom relief. For biotech stakeholders, the coverage underscores a recurring development challenge in women’s health: heterogeneity of symptoms, evidence scarcity, and difficulty building late-stage registries and endpoints that can support broad regulatory labeling.